RxDoctor Payments DataLook up a doctor →

Matthew Clary, MD

Ophthalmology · Columbia, SCNPI 1538345004

Payments from drug & device makers

$123,491in general payments, 2019–2025

Across 781 payments — averaging $158.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$88K
  • Sight Sciences, Inc.$19K
  • Alcon Research LLC$4K
  • Alcon$4K
  • Sun Pharmaceutical Industries Inc.$2K
  • Ocular Therapeutix, Inc.$731
  • plus $6K from 28 others

What the payments were for

  • Consulting fees$3,0503%
  • Speaking & faculty fees$93,95079%
  • Travel & lodging$6,1805%
  • Food & beverage$15,80213%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,491 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$676,847
Medicare patients
1,433
Services billed
4,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost170$80,493
RestasisCyclosporine50$67,935
VyzultaLatanoprostene Bunod50$23,754
Cyclosporine31$19,377
XiidraLifitegrast16$17,800
IlevroNepafenac48$17,744
ProlensaBromfenac Sodium47$16,582
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol78$15,789
SimbrinzaBrinzolamide/Brimonidine Tart68$14,744
CequaCyclosporine14$14,171
CombiganBrimonidine Tartrate/Timolol27$12,796
Alphagan PBrimonidine Tartrate35$11,097
Travoprost32$7,676
RocklatanNetarsudil Mesylat/Latanoprost18$6,807
Brimonidine Tartrate111$5,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$87,881$172,321282 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$578$41,55466 claims
NovartisIlevro$600$17,74448 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$447$16,58247 claims
AlconSimbrinza$3,559$14,74468 claims
Sun Pharmaceutical Industries Inc.Cequa$1,651$14,17114 claims
Aerie Pharmaceuticals, Inc.Rocklatan$92$6,80718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →